Clinical Trials Directory

Trials / Unknown

UnknownNCT05273333

Effect of Ultra-gyn® on Vulvovaginal Candidiasis

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Biocodex · Industry
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The aim of this post-market clinical follow up study is to confirm the performance and the safety of Ultra-gyn® (when used in accordance with its approved labelling)

Conditions

Interventions

TypeNameDescription
DEVICEUltra-gyn®Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.

Timeline

Start date
2022-02-23
Primary completion
2022-07-01
Completion
2022-12-01
First posted
2022-03-10
Last updated
2022-03-10

Locations

1 site across 1 country: Mauritius

Source: ClinicalTrials.gov record NCT05273333. Inclusion in this directory is not an endorsement.

Effect of Ultra-gyn® on Vulvovaginal Candidiasis (NCT05273333) · Clinical Trials Directory